Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI ) by John F. Heerdink, Jr. 21 hours ago Read more From EoE to CAR‑T: The Overachiever’s Guide to Eupraxia and Legend Biotech in 2026 -( $EPRX $JNJ $LEGN ) by John F. Heerdink, Jr. 2 days ago Read more Autodesk’s $3.6 Billion Wrench Turn: Why Wall Street Suddenly Loves Maintenance -( $ADSK $AMWL $FMC ) by John F. Heerdink, Jr. May 29, 2026 Read more Viral Threats, Rational Markets: What GeoVax Told Tribe Public About Ebola, Marburg, Hantavirus and Beyond by John F. Heerdink, Jr. May 28, 2026 Read more Ebola, Marburg, Hantavirus, Mpox and Beyond: Join Tribe Public’s CEO Event on Infectious Disease Preparedness -( May 28, $GOVX) by John F. Heerdink, Jr. May 27, 2026 Read more Vaccine Valuations: Lilly’s 4 Billion Dollar Bet & GeoVax’s Focused Grind – ( $GOVX $LLY ) by John F. Heerdink, Jr. May 26, 2026 Read more Atlanta Joins the Ebola Watchlist: How One Airport and One Biotech Are Keeping Calm and Carrying On -( $DAL $GOVX $XBI ) by John F. Heerdink, Jr. May 24, 2026 Read more The Insulin Pump That Could Spark a Bidding War: Modular Medical’s Pivot Targets Millions Still on Manual Injections -( $ABT $JNJ $MDT $MMED $MODD $PODD $TNDM ) by John F. Heerdink, Jr. May 22, 2026 Read more Stifel Places Target On Eupraxia During National Eosinophil Awareness Week -( $EPRX $SNY $REGN $TAK ) by John F. Heerdink, Jr. May 20, 2026 Read more Reverse Merger, Forward Thinking: InMed, Mentari and the Billion‑Patient Migraine Market -( $INM ) by John F. Heerdink, Jr. May 19, 2026 Read more Read more
